Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Merus N.V. CS (NQ: MRUS )

53.13 +0.23 (+0.43%)
Streaming Delayed Price Updated: 3:35 PM EDT, Jun 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Merus N.V. CS

< Previous 1 2 Next >
Merus N.V. Announces Proposed Public Offering of Common Shares
From Merus N.V.
Via GlobeNewswire
Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023
From Merus N.V.
Via GlobeNewswire
Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration
From Merus N.V.
Via GlobeNewswire
Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer
From Merus N.V.
Via GlobeNewswire
Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer
From Merus N.V.
Via GlobeNewswire
Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference 2023
From Merus N.V.
Via GlobeNewswire
Merus Announces Financial Results for the First Quarter 2023 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Merus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)
From Merus N.V.
Via GlobeNewswire
Merus Announces Publication of an Abstract on Petosemtamab in Advanced Gastric/Esophageal Adenocarcinoma for Presentation at the AACR Annual Meeting 2023
From Merus N.V.
Via GlobeNewswire
Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 and Provides a Program and Regulatory Update
From Merus N.V.
Via GlobeNewswire
Merus Announces Publication of an Abstract on Preclinical Mechanism of Action of MCLA-129 Selected for Poster Presentation at the AACR Annual Meeting 2023
Poster presentation: Tuesday, April 18, 2023, 1:30-5:30 p.m. ET 
From Merus N.V.
Via GlobeNewswire
Merus Announces Petosemtamab in Previously Treated Head and Neck Squamous Cell Carcinoma Abstract Selected for Plenary Session Oral Presentation at the AACR Annual Meeting 2023
From Merus N.V.
Via GlobeNewswire
Merus Announces Financial Results for the Fourth Quarter and Full Year 2022 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Merus to Participate in Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
CORRECTING and REPLACING --Merus Provides 2023 Outlook
From Merus N.V.
Via GlobeNewswire
Merus Provides 2023 Outlook
From Merus N.V.
Via GlobeNewswire
Merus to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference
From Merus N.V.
Via GlobeNewswire
Merus Announces Financial Results for the Third Quarter and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
From Merus N.V.
Via GlobeNewswire
Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
From Merus N.V.
Via GlobeNewswire
Promising Developments in Breast Cancer Treatments Ahead in 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 12, 2022 – USA News Group – So far in 2022, there have already been some impressive developments in the battle against... 
Via FinancialNewsMedia
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.